A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

October 5, 2026

Study Completion Date

October 5, 2026

Conditions

Acute Lymphoblastic LeukemiaLeukemia

Interventions

DRUG

Ponatinib

Given by PO

DRUG

Venetoclax

Given by PO

DRUG

Mini-hyper CVD

Given by IV (vein)

Trial Locations (1)

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER